Vascular Biology |
Promoter Via a Functional NF
B SiteFrom Experimental Pediatric Cardiology (S.B., C.Z., R.S.B., T.D., J.H., A.G.), Department of Pediatric Cardiology and Congenital Heart Disease, German Heart Center Munich at the TU Munich, Germany; Laboratory of Biochemistry and Cellular Biology (C.M.), University of Namur, Belgium; Faculty of Chemistry/Biochemistry (T.K.), University of Kaiserslautern, Germany.
Correspondence to Agnes Görlach, MD, Experimental Pediatric Cardiology, Department of Pediatric Cardiology and Congenital Heart Disease, German Heart Center Munich at the TU Munich, Lazarettstr. 36, D-80636 Munich, Germany. E-mail goerlach{at}dhm.mhn.de
| Abstract |
|---|
|
|
|---|
B). Recently, the transcription factor hypoxia-inducible factor-1 (HIF-1), known to mediate gene expression by hypoxia, has been found to be also activated by nonhypoxic factors in a redox-sensitive manner. We therefore aimed to elucidate the link between these 2 important redox-sensitive transcription factors.
Methods and Results In pulmonary artery smooth muscle cells, reactive oxygen species generated either by exogenous H2O2 or by a NOX4-containing NADPH oxidase stimulated by thrombin activated or induced NF-
B and HIF-1
. The reactive oxygen species-mediated HIF-1
induction occurred on the transcriptional level and was dependent on NF-
B. Transfection experiments with wild-type or mutant HIF-1
promoter constructs revealed the presence of a yet unidentified NF-
B binding element. Gel shift analyses and chromatin immunoprecipitation verified binding of NF-
B to this site. Furthermore, reactive oxygen species enhanced expression of plasminogen activator inhibitor-1, which was prevented by dominant-negative I
B or mutation of the HIF-1 binding site within the plasminogen activator inhibitor-1 promoter.
Conclusion These findings show for the first time to our knowledge that reactive oxygen species directly link HIF-1
and NF-
B, implicating an important pathophysiological role of this novel pathway in disorders associated with elevated levels of reactive oxygen species.
ROS generated by exogenous H2O2 or by a NOX4-containing NADPH oxidase stimulated by thrombin, transcriptionally induced HIF-1
via a novel NF
B binding site in the HIF-1
promoter. Thus, ROS directly link these 2 major transcription factors, implicating an important role of this novel pathway in disorders associated with oxidative stress.
Key Words: hypoxia-inducible factor NADPH oxidase nuclear factor kappa B reactive oxygen species thrombin
| Introduction |
|---|
|
|
|---|
Moderate levels of reactive oxygen species (ROS), especially superoxide anions and hydrogen peroxide, have been shown to activate signaling cascades mediating the responses to vasoactive peptides, growth factors, cytokines, hormones, and coagulation factors, as well as to physical and chemical stress. ROS participate in the regulation of vascular proliferation, migration, apoptosis, modification of the extracellular matrix, and procoagulant activity.49 Moreover, ROS can activate angiogenesis,10 a process known to be primarily mediated by vascular endothelial growth factor under hypoxia. Under hypoxia, vascular endothelial growth factor expression is induced by the transcription factor hypoxia-inducible factor-1 (HIF-1).11 Aside from vascular endothelial growth factor, HIF-1 regulates >100 genes encoding for metabolic enzymes, growth factors, and factors contributing to modulation of extracellular matrix and thrombosis such as plasminogen activator inhibitor-1 (PAI-1).1215
HIF-1 is composed of an inducible
-subunit (HIF-1
) and a constitutive ß-subunit (also termed ARNT).12 HIF-1
contains an oxygen-dependent degradation domain that, when hydroxylated by specific prolyl hydroxylases, binds the von Hippel Lindau protein, leading to HIF-1
ubiquitinylation and degradation by the 26S proteasome. At low oxygen levels, the prolyl hydroxylases lose their activity, which prevents von Hippel Lindau protein binding.13,16 This results in HIF-1
stabilization, nuclear translocation, dimerization with ARNT, recruitment of coactivators, and binding to hypoxia-response elements in the promoter of target genes.
Recently, HIF-1
has also been shown to be upregulated under normoxia in response to growth factors, thrombin, lipopolysaccharide, angiotensin II, cytokines, or insulin.1722 Interestingly, many of these factors also stimulate the generation of ROS, whereas inhibition of ROS formation decreased HIF-1
protein levels by thrombin, PDGF, transforming growth factor-ß, angiotensin II, cytokines, or CoCl2,18,20,21,23 suggesting that ROS play an important role in the regulation of HIF-1. However, although a number of details of how hypoxia stabilizes HIF-1
have been unraveled, the mechanisms by which ROS induce HIF-1
have not been fully elucidated. We therefore aimed to investigate how ROS either applied exogenously as mild oxidative stress mimicked by low levels of H2O2, by overexpression of the NADPH oxidase subunit NOX4 or endogenously, induced by the NADPH oxidase activator thrombin, would regulate HIF-1
in pulmonary artery smooth muscle cells (PASMCs). We identified a novel pathway in which ROS upregulate HIF-1
transcription by activating NF
B, thus linking these important pathways in a common mechanism induced by ROS.
| Materials and Methods |
|---|
|
|
|---|
Cell Culture
Human PASMCs were from Cambrex and cultured in the medium provided. PASMCs (passages 3 to 11) were serum-deprived for 24 hours before stimulation with thrombin (3 U/mL) or H2O2 (50 µmol/L). Cell viability was not affected by this treatment. For reporter gene assays, human embryonic kidney cells (HEK293) were grown in Dulbeccos modified Eagle medium supplemented with 10% fetal calf serum, 100 U/mL penicillin, and 100 µg/mL streptomycin.
Plasmids and Luciferase Assays
Expression vectors for the NF
B subunits p50 and p65, dominant-negative I
B
, dominant-negative I
K
, p22phox, and NOX4, as well as the HIF-1
promoter luciferase constructs HIF1
-538 and HIF1
-106, the PAI-1 promoter constructs PAI-796 and PAI-796m, and the luciferase construct NF
B-Luc have been described.2427 The construct HIF1
-538m containing a mutated NF
B site at 197 bp was generated with the QuickChange mutagenesis kit (Promega) and confirmed by sequencing. Short hairpin RNA encoding for 19mer siRNA against HIF-1
(1272 to 1290 nt) (5'-GCA ACG ACA CAG AAA CTG A-3'), NOX428 and for control siRNA (siCtr)28 were created using the siSTRIKE U6 Hairpin Cloning System (Promega). Transfection of PASMCs and HEK293 cells was performed as described.24,27 After 24 hours, transfected cells were serum-starved for 16 hours and then stimulated. Transfection efficiency was 60% to 70%. A Renilla luciferase expression vector (pRLSV40) (Promega) was co-transfected in reporter gene assays to adjust for variations in transfection efficiencies.
Measurement of ROS Production
ROS generation was measured using the fluoroprobe 5- (and 6-) chloromethyl-2',7'-dichlorodihydrofluorescein diacetate acetyl ester (CM-H2DCFDA; Molecular Probes) as described.25
Immunofluorescence
Immunofluorescence using a p50 antibody (Santa Cruz) and a Alexa 488-coupled secondary antibody (Mobitech) was performed as described.18
Northern Blot Analysis
Total RNA was isolated as described18 and analyzed by Northern blot. Hybridization was performed using digoxigenin-labeled antisense RNA probes for HIF-1
or NOX4 overnight at 65°C.
Western Blot Analysis
Western blot analysis was performed as described previously18 using antibodies against HIF-1
(Transduction), PAI-1 (American Diagnostica), ß-Actin (Dako), and goat anti-mouse or anti-rabbit immunoglobulin G (Calbiochem). The enhanced chemiluminescence Western blotting system (Amersham) was used for detection.
Electrophoretic Mobility Shift Assay
Nuclear extraction was performed as described.18,27 The oligonucleotides contained the sequence 5'-ggg gtg ggg act tgc cgc ctg cg-3' from the HIF-1
promoter. For competition assays, unlabeled oligonucleotides were added 15 minutes before adding the labeled probe at 25-fold molar concentration. Supershift analysis was performed by addition of a p65 antibody (Santa Cruz).
Chromatin Immunoprecipitation
Proteins were cross-linked with formaldehyde. After adding 0.125 mol/L glycine, cell lysis buffer (5 mmol/L PIPES, 1 mol/L KCl, 10% NP40) and nuclear lysis buffer (5 mmol/L PIPES, 85 nmol/L KCl, 0.5% NP40) supplemented with protease inhibitors were added, followed by sonication and centrifugation. The supernatant was precleared with Sepharose beads (Amersham Biosciences), incubated with p50 or p65 antibodies (Santa Cruz) overnight, and then with beads for 2 hours. The complexes were eluted with buffer (100 mmol/L NaHCO3, 1% SDS) and incubated with RNAse A. DNA was purified using QIAquick polymerase chain reaction purification kit (Qiagen). Polymerase chain reaction was performed with primers for the HIF-1
promoter (forward: 5'-gaa cag aga gcc cag cag ag-3'; reverse: 5'-tgt gca ctg agg agc tga gg-3') flanking the NF
B binding site (197/188 bp) at 55°C for 35 cycles or primers for the PAI-1 promoter (forward: 5'-gct ctt tcc tgg agg tgg tc-3'; reverse: 5'-ggg cac aga gag agt ctg ga-3').
Statistical Analysis
Values presented are means±SEM. Results were compared by ANOVA for repeated measurements followed by Student-Newman-Keuls t test. P
0.05 was considered statistically significant.
| Results |
|---|
|
|
|---|
mRNA and Protein Are Increased by ROS Via a Transcriptional Mechanism
protein but also HIF-1
mRNA levels, with a maximal response at 50 µmol/L (Figure 1A). Treatment with 50 µmol/L H2O2 for increasing time periods transiently elevated HIF-1
mRNA and protein with maximal levels at 1 and 2 hours, respectively (Figure 1B). We have previously shown that thrombin activates ROS production.23,24 Indeed, stimulation with thrombin resulted in a time-dependent increase in ROS levels, peaking at 4 hours (Figure 2A). Interestingly, thrombin concomitantly enhanced HIF-1
mRNA and protein levels, peaking at 2 and 4 hours, respectively (Figure 2B). Treatment with the antioxidant N-acetylcysteine inhibited thrombin-stimulated HIF-1
mRNA and protein expression by 85±8% and 94±4%, respectively (Figure 2C). Similarly, siRNA targeting the NADPH oxidase subunit NOX4, which is known to contribute to ROS production in PASMCs,25 reduced NOX4 mRNA levels by 80±7% and decreased HIF-1
levels to a similar degree (Figure 2D), further suggesting the involvement of ROS. Consistently, similar to H2O2 or thrombin, overexpression of NOX4 enhanced HIF-1
mRNA and protein levels (Figure 2D), indicating that a NOX4-containing NADPH oxidase contributes to thrombin-induced HIF-1
regulation. Comparable results were obtained by overexpression of the NADPH oxidase subunit p22phox (data not shown). Because upregulation of HIF-1
mRNA by H2O2, NOX4, and thrombin suggested the involvement of a transcriptional mechanism, PASMCs were pretreated with the transcription inhibitor actinomycin D (5 µmol/L). This treatment diminished the induction of HIF-1
mRNA and protein by H2O2 by 85±8% and 92±7% or by thrombin by 94±5% and 82±9%, respectively (supplemental Figure I, available online at http://atvb.ahajournals.org).
|
|
NF
B Is Activated by H2O2 and Thrombin and Increases HIF-1
Expression
The transcription factor NF
B has been suggested to contribute to the transcriptional response to ROS.29 Indeed, H2O2 or thrombin promoted nuclear translocation of NF
B p50 in PASMCs (supplemental Figure II) and increased NF
B activity in HEK293 cells transfected with a NF
B-dependent luciferase construct (NF
B-luc) (Figure 3A). Cotransfection of dominant-negative I
B
(I
Bdn) abolished NF
B activation by these stimuli.
|
To determine the involvement of the NF
B pathway in the regulation of HIF-1
, PASMCs were transfected with vectors encoding the NF
B subunits p50 and p65 (NF
B) or I
Bdn. NF
B, but not I
Bdn, enhanced HIF-1
mRNA and protein levels. However, I
Bdn diminished HIF-1
mRNA and protein induction by H2O2 by 82±9% and 79±8%, respectively, and inhibited HIF-1
mRNA and protein levels in the presence of thrombin by 89±8% and 95±6%, respectively (Figure 3B).
The HIF-1
Promoter Contains a Functional NF
B Binding Site
Next, we performed reporter gene assays using a construct containing the HIF-1
promoter (538 to +284) fused to the luciferase gene (HIF1
-538). Stimulation with H2O2, thrombin, or overexpression of NOX4 or p22phox enhanced HIF-1
promoter activity (Figure 4A). A similar response was observed when the NF
B subunits p50 and p65 were co-expressed. However, H2O2-stimulated or thrombin-stimulated HIF-1
promoter activity was decreased in the presence of dominant-negative I
B
or I
K
. In contrast, luciferase activity of the construct containing only 106 bp of the HIF-1
promoter (HIF1
-106) could not be enhanced by thrombin, H2O2, or NF
B (Figure 4A). Analysis of the HIF-1
promoter revealed a putative NF
B site at 197/188 bp. To determine whether this site is functional, site-directed mutagenesis was performed on the HIF1
-538 construct. The reporter gene assays showed that the mutated HIF-1
promoter failed to respond to H2O2, thrombin, or overexpression of NF
B, I
Bdn, I
Kdn, NOX4, or p22phox (Figure 4A). These data indicate that the site 197/188 was responsible for transcriptional activation of HIF-1
by NF
B.
|
Consistently, nuclear extracts from PASMCs stimulated with H2O2 or thrombin showed enhanced binding to an oligonucleotide containing this NF
B site as demonstrated by electrophoretic mobility shift assays (supplemental Figure III). This binding was diminished by a 25-fold excess of unlabeled oligonucleotides. Addition of an antibody against p65 prevented binding of this complex.
Binding of p50 and p65 to the HIF-1
promoter was also detected by chromatin immunoprecipitation (Figure 4B). In contrast, as expected, chromatin immunoprecipitation did not reveal binding of p50 to the PAI-1 promoter (Figure 4B). These data clearly show that p50 and p65 specifically bind to the HIF-1
promoter element 197/188.
NF
B Modulates the Expression of the HIF-1 Target Gene PAI-1
PAI-1 has been described to be regulated by HIF-1 in response to hypoxia.15 Similarly, thrombin enhanced luciferase activity mediated by the human PAI-1 promoter (PAI-796), whereas depletion of HIF-1
by siRNA prevented this response (supplemental Figure IV). To determine whether induction of HIF-1
via NF
B would play a role in PAI-1 regulation, NF
B was co-expressed with PAI-796, which contains a hypoxia response element, but no NF
B binding sites. Reporter assays revealed that NF
B increased luciferase activity similar to H2O2 or thrombin (Figure 5A), whereas I
Bdn diminished H2O2-stimulated and thrombin-stimulated PAI-1 promoter activity. In contrast, mutation of the hypoxia-response elements blunted luciferase activity induced by NF
B, H2O2 or thrombin (Figure 5A). Consistently, overexpression of NF
B increased PAI-1 secretion from PASMCs, whereas I
Bdn decreased PAI-1 secretion by H2O2 or thrombin (Figure 5B).
|
| Discussion |
|---|
|
|
|---|
transcription via binding of NF
B to a novel site in the HIF-1
promoter. Together with the observation that this pathway regulates the expression of PAI-1, these findings suggest an important role of this novel mechanism in various disorders associated with high levels of ROS and thrombotic activity.
Nonhypoxic Stimulation of HIF-1
: Role of ROS
HIF-1 has been initially described to specifically mediate the response to hypoxia because of its instability under normoxia. Despite these findings, HIF-1
protein has been shown to be upregulated under normoxia in response to growth factors, hormones, coagulation factors, cytokines, and vasoactive peptides.17,18,20,21,30,31 In this study we demonstrated that low levels of H2O2 as well as activation of ROS production by thrombin increase HIF-1
mRNA and protein levels. Interestingly, stimulation with thrombin rapidly increased ROS levels within 30 minutes of exposure followed by a second more prominent peak at 4 hours of stimulation. Concomitantly, HIF-1
protein was rapidly increased, followed by a sustained increase in HIF-1
mRNA levels peaking at 2 hours, which was then followed by a substantial increase in HIF-1
protein peaking at 4 hours. Although actinomycin D prevented thrombin and H2O2-induced HIF-1
mRNA and protein upregulation clearly pointing to a transcriptional mechanism, it cannot be excluded that the initial rapid increase in ROS and HIF-1
protein levels by thrombin may also involve HIF-1
stabilization, possibly by affecting the activity of prolyl hydroxylases. Furthermore, the decrease in HIF-1
protein levels after prolonged exposure to thrombin despite a sustained elevation of HIF-1
mRNA and ROS levels may be the result of a compensatory mechanism, such as upregulation of prolyl hydroxylases. Indeed, prolyl hydroxylases have been shown to be HIF target genes.32 However, further experiments are required to dissect the exact contribution of transcriptional versus other mechanisms regulating HIF-1
levels in response to thrombin and ROS at different time points.
The importance of ROS derived from a NOX4-containing NADPH oxidase in response to thrombin was supported by our findings that antioxidants and depletion of NOX4 decreased HIF-1
upregulation by thrombin, whereas overexpression of NOX4 increased HIF-1
mRNA and protein. Similar results have been obtained with the NADPH oxidase subunit p22phox (data not shown) consistent with our previous observation that p22phox antisense oligonucleotides or antioxidants prevented HIF-1
protein upregulation by thrombin, transforming growth factor-ß1, or PDGF in vascular smooth muscle cells.18 Importantly, however, an effect of thrombin or ROS on HIF-1
mRNA levels has not been reported previously.
A role for NADPH oxidase-derived ROS in the regulation of HIF-1
was further suggested by an in vivo study in mice in which overexpression of p22phox increased ROS and HIF-1
protein levels in smooth muscle cells.33 Consistently, overexpression of CuZnSOD, which promotes the formation of H2O2 from superoxide anions, enhanced HIF-1
protein levels in PASMCs, whereas catalase, which promotes the degradation of H2O2, prevented thrombin-induced and CoCl2-induced HIF-1
protein,23 further confirming that enhanced H2O2 levels are important in upregulating HIF-1
under normoxia in smooth muscle cells.
In contrast to these findings obtained under normoxic conditions (21% oxygen) in PASMCs, the role of ROS in the regulation of HIF-1
under hypoxia appears to be complex, and controversial data exist showing that ROS can promote or prevent the induction of HIF-1
under different oxygen concentrations in different cell types.34 Although the reasons for the conflicting data are not clear to date, and await further experimental clarification, the cellular redox steady-state and microenvironmental conditions together with cell-type specific properties appear to be crucial. This is supported by findings showing that in HepG2 hepatoma cells cultivated under 16% or 8% oxygen, expression of active Rac, known to activate NADPH oxidases under normoxic conditions, decreased HIF-1
protein levels.35 However, this response was not observed or even reversed when these cells were cultivated under 21% oxygen (data not shown) consistent with our study in which expression of NOX4 enhanced HIF-1
levels in PASMCs cultivated under 21% oxygen. These findings suggest that ROS are important signals in fine-tuning HIF-1
levels even in a narrow range of different microenvironmental conditions. They further implicate that there are no "absolute" ROS levels that will have a specific effect on HIF-1
, but that a shift toward a pro-oxidant or anti-oxidant state relative to a cells redox steady-state will affect HIF-1
levels.
NF
B Is a Transcriptional Regulator of HIF-1
Our data show for the first time that enhanced levels of ROS by H2O2, NOX4, or thrombin induce HIF-1
transcription because these stimuli increased HIF-1
promoter activity, whereas actinomycin D almost completely prevented thrombin-induced and H2O2-induced HIF-1
mRNA and protein levels.
Although enhanced HIF-1
mRNA levels have also been described by angiotensin II, lipopolysaccharide, IL-1, or HGF,19,31,3638 only limited data exist with regard to the underlying mechanisms in particular with regard to the involvement of transcriptional regulation. Importantly, the involvement of ROS in transcriptional regulation of HIF-1
has not yet been addressed.
In this study we show that enhanced HIF-1
transcription by ROS was mediated by NF
B. Indeed, overexpression of NF
B increased HIF-1
mRNA levels and stimulated HIF-1
promoter activity similar to thrombin or H2O2, whereas dominant-negative I
B
and I
K
, which inhibit activation of NF
B, decreased H2O2-dependent and thrombin-dependent induction of HIF-1
mRNA and promoter activity. We further identified a NF
B binding site in the HIF-1
promoter at 197/188 bp. Mutation of this site abolished stimulation of HIF-1
promoter activity by NF
B, H2O2, NOX4, and thrombin, confirming that ROS transcriptionally upregulate HIF-1
by activation of NF
B. Consistently, electrophoretic mobility shift assays and chromatin immunoprecipitation demonstrated that the NF
B subunits p50 and p65 were able to bind to the HIF-1
promoter at this specific site.
NF
B has been previously shown to contribute to the regulation of HIF-1
protein, but not to HIF-1
mRNA, by tumor necrosis factor-
or colchicine in fibroblasts, and to HIF-1
translation by HGF in HepG2 cells.37,3941 Thus, the transcriptional regulation of HIF-1
by ROS and NF
B may act in concert with translation and stabilization of HIF-1
and appears to be cell type and/or stimulus specific. A recent study showed upregulation of HIF-1
mRNA by lipopolysaccharide, which was prevented by the nonspecific NF
B inhibitor bortezomib in monocytes.38 Interestingly, in this study it was suggested that this response was mediated by binding of NF
B to a site within the HIF-1
promoter although this site has not been verified by mutagenesis. In contrast to the NF
B site we identified in the HIF-1
promoter at 197/188 bp by site-directed mutagenesis, gel shift analysis and chromatin immunoprecipitation, the NF
B site suggested in this earlier study lies at position +149 bp, well within the HIF-1
5'-untranslated region. Thus, its contribution to transcriptional activity is unclear. In contrast, our data demonstrated that the truncated (HIF1
-106) and the mutated (HIF1
-538m) HIF-1
promoter constructs, both of which exclude the NF
B site at 197/188 bp but include the full untranslated region and the intact NF
B consensus sequence at +149 bp, were not modulated by H2O2, thrombin, or the NF
B subunits. This confirms that a NF
B binding element at 197/188 bp upstream of the transcription initiation site of the HIF-1
promoter is functional and is responsible for the transcriptional activation of HIF-1
by H2O2, thrombin, and NADPH oxidases.
The importance of NF
B as a regulatory factor of HIF-1 in response to exogenous or endogenous ROS was further highlighted by our findings that H2O2, thrombin, and NF
B increased promoter activity and expression of the HIF-1 target gene PAI-1. This response was dependent on HIF-1, because the PAI-1 promoter construct that does not contain a NF
B site did not respond to H2O2, thrombin, or NF
B when the HIF-1binding hypoxia response element in the PAI-1 promoter was mutated or when HIF-1
was downregulated. PAI-1, known as an inhibitor of fibrinolysis, also plays an important role in matrix remodeling and angiogenesis and has been implicated in the pathogenesis of many cardiovascular disorders associated with enhanced levels of ROS and thrombin including systemic and pulmonary hypertension and atherosclerosis.42 Interestingly, these disorders have also been associated with increased activity of NF
B, suggesting that this pathway can upregulate HIF-1
even under normoxia in the presence of ROS or on activation of the coagulation cascade.
In summary, this study shows that elevated levels of ROS can activate NF
B involving I
K
and I
B
. This results in enhanced transcription of HIF-1
via a specific element in the HIF-1
promoter leading to increased HIF-1
mRNA and protein levels, which mediate the upregulation of PAI-1 and possibly other HIF-1 target genes. Because enhanced ROS, thrombotic activity, and matrix remodeling have been implicated in cardiovascular disorders including systemic and pulmonary hypertension and atherosclerosis, as well as in tumor progression, the findings that HIF-1
is a target gene of NF
B under normoxia indicate a new role for HIF-1 in the pathogenesis of these diseases independent of oxygen availability and suggest the requirement of new therapeutic strategies for these disorders.
| Acknowledgments |
|---|
Sources of Funding
This work was supported by DFG GO709/4-4, the 6th European framework program (EUROXY) to A.G., and Fondation Leducq to A.G. and J.H., and by grants from DFG SFB 402 A1, GRK 335, Fonds der Chemischen Industrie, and Deutsche Krebshilfe (106429) to T.K.
Disclosure
C.M. is a senior research associate of FNRS (Belgium).
| Footnotes |
|---|
| References |
|---|
|
|
|---|
2. Madamanchi NR, Vendrov A, Runge MS. Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol. 2005; 25: 2938.
3. Lassegue B, Griendling KK. Reactive oxygen species in hypertension; An update. Am J Hypertens. 2004; 17: 852860.[CrossRef][Medline] [Order article via Infotrieve]
4. Gorlach A, Kietzmann T, Hess J. Redox signaling through NADPH oxidases: involvement in vascular proliferation and coagulation. Ann N Y Acad Sci. 2002; 973: 505507.[CrossRef][Medline] [Order article via Infotrieve]
5. Irani K. Oxidant signaling in vascular cell growth, death, and survival : a review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling. Circ Res. 2000; 87: 179183.
6. Cai H. Hydrogen peroxide regulation of endothelial function: origins, mechanisms, and consequences. Cardiovasc Res. 2005; 68: 2636.
7. Clempus RE, Griendling KK. Reactive oxygen species signaling in vascular smooth muscle cells. Cardiovasc Res. 2006; 71: 216225.
8. Ardanaz N, Pagano PJ. Hydrogen peroxide as a paracrine vascular mediator: regulation and signaling leading to dysfunction. Exp Biol Med (Maywood). 2006; 231: 237251.
9. Gorlach A. Redox regulation of the coagulation cascade. Antioxid Redox Signal. 2005; 7: 13981404.[CrossRef][Medline] [Order article via Infotrieve]
10. Ushio-Fukai M, Alexander RW. Reactive oxygen species as mediators of angiogenesis signaling: role of NAD(P)H oxidase. Mol Cell Biochem. 2004; 264: 8597.[CrossRef][Medline] [Order article via Infotrieve]
11. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996; 16: 46044613.[Abstract]
12. Semenza GL. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol. 2000; 88: 14741480.
13. Maxwell PH. Hypoxia-inducible factor as a physiological regulator. Exp Physiol. 2005; 90: 791797.
14. Wenger RH, Stiehl DP, Camenisch G. Integration of oxygen signaling at the consensus HRE. Sci STKE. 2005; 2005: re12.
15. Kietzmann T, Roth U, Jungermann K. Induction of the plasminogen activator inhibitor-1 gene expression by mild hypoxia via a hypoxia response element binding the hypoxia-inducible factor-1 in rat hepatocytes. Blood. 1999; 94: 41774185.
16. Ruas JL, Poellinger L. Hypoxia-dependent activation of HIF into a transcriptional regulator. Semin Cell Dev Biol. 2005; 16: 514522.[CrossRef][Medline] [Order article via Infotrieve]
17. Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem. 2002; 277: 3820538211.
18. Gorlach A, Diebold I, Schini-Kerth VB, Berchner-Pfannschmidt U, Roth U, Brandes RP, Kietzmann T, Busse R. Thrombin activates the hypoxia-inducible factor-1 signaling pathway in vascular smooth muscle cells: Role of the p22(phox)-containing NADPH oxidase. Circ Res. 2001; 89: 4754.
19. Blouin CC, Page EL, Soucy GM, Richard DE. Hypoxic gene activation by lipopolysaccharide in macrophages: implication of hypoxia-inducible factor 1alpha. Blood. 2004; 103: 11241130.
20. Richard DE, Berra E, Pouyssegur J. Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1alpha in vascular smooth muscle cells. J Biol Chem. 2000; 275: 2676526771.
21. Haddad JJ, Land SC. A non-hypoxic, ROS-sensitive pathway mediates TNF-alpha-dependent regulation of HIF-1alpha. FEBS Lett. 2001; 505: 269274.[CrossRef][Medline] [Order article via Infotrieve]
22. Zelzer E, Levy Y, Kahana C, Shilo BZ, Rubinstein M, Cohen B. Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1alpha/ARNT. Embo J. 1998; 17: 50855094.[CrossRef][Medline] [Order article via Infotrieve]
23. BelAiba RS, Djordjevic T, Bonello S, Flugel D, Hess J, Kietzmann T, Gorlach A. Redox-sensitive regulation of the HIF pathway under non-hypoxic conditions in pulmonary artery smooth muscle cells. Biol Chem. 2004; 385: 249257.[CrossRef][Medline] [Order article via Infotrieve]
24. Djordjevic T, Hess J, Herkert O, Gorlach A, BelAiba RS. Rac regulates thrombin-induced tissue factor expression in pulmonary artery smooth muscle cells involving the nuclear factor-kappaB pathway. Antioxid Redox Signal. 2004; 6: 713720.[CrossRef][Medline] [Order article via Infotrieve]
25. Djordjevic T, BelAiba RS, Bonello S, Pfeilschifter J, Hess J, Gorlach A. Human urotensin II is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells. Arterioscler Thromb Vasc Biol. 2005; 25: 519525.
26. Minet E, Ernest I, Michel G, Roland I, Remacle J, Raes M, Michiels C. HIF1A gene transcription is dependent on a core promoter sequence encompassing activating and inhibiting sequences located upstream from the transcription initiation site and cis elements located within the 5'UTR. Biochem Biophys Res Commun. 1999; 261: 534540.[CrossRef][Medline] [Order article via Infotrieve]
27. Dimova EY, Kietzmann T. Cell type-dependent regulation of the hypoxia-responsive plasminogen activator inhibitor-1 gene by upstream stimulatory factor-2. J Biol Chem. 2006; 281: 29993005.
28. Petry A, Djordjevic T, Weitnauer M, Kietzmann T, Hess J, Gorlach A. NOX2 and NOX4 mediate proliferative response in endothelial cells. Antioxid Redox Signal. 2006; 8: 14731484.[CrossRef][Medline] [Order article via Infotrieve]
29. Kabe Y, Ando K, Hirao S, Yoshida M, Handa H. Redox regulation of NF-kappaB activation: distinct redox regulation between the cytoplasm and the nucleus. Antioxid Redox Signal. 2005; 7: 395403.[CrossRef][Medline] [Order article via Infotrieve]
30. Hellwig-Burgel T, Rutkowski K, Metzen E, Fandrey J, Jelkmann W. Interleukin-1beta and tumor necrosis factor-alpha stimulate DNA binding of hypoxia-inducible factor-1. Blood. 1999; 94: 15611567.
31. Page EL, Robitaille GA, Pouyssegur J, Richard DE. Induction of hypoxia-inducible factor-1alpha by transcriptional and translational mechanisms. J Biol Chem. 2002; 277: 4840348409.
32. Marxsen JH, Stengel P, Doege K, Heikkinen P, Jokilehto T, Wagner T, Jelkmann W, Jaakkola P, Metzen E. Hypoxia-inducible factor-1 (HIF-1) promotes its degradation by induction of HIF-alpha-prolyl-4-hydroxylases. Biochem J. 2004; 381: 761767.[CrossRef][Medline] [Order article via Infotrieve]
33. Khatri JJ, Johnson C, Magid R, Lessner SM, Laude KM, Dikalov SI, Harrison DG, Sung HJ, Rong Y, Galis ZS. Vascular oxidant stress enhances progression and angiogenesis of experimental atheroma. Circulation. 2004; 109: 520525.
34. Kietzmann T, Gorlach A. Reactive oxygen species in the control of hypoxia-inducible factor-mediated gene expression. Semin Cell Dev Biol. 2005; 16: 474486.[CrossRef][Medline] [Order article via Infotrieve]
35. Gorlach A, Berchner-Pfannschmidt U, Wotzlaw C, Cool RH, Fandrey J, Acker H, Jungermann K, Kietzmann T. Reactive oxygen species modulate HIF-1 mediated PAI-1 expression: involvement of the GTPase Rac1. Thromb Haemost. 2003; 89: 926935.[Medline] [Order article via Infotrieve]
36. Thornton RD, Lane P, Borghaei RC, Pease EA, Caro J, Mochan E. Interleukin 1 induces hypoxia-inducible factor 1 in human gingival and synovial fibroblasts. Biochem J. 2000; 350 Pt 1: 307312.
37. Tacchini L, De Ponti C, Matteucci E, Follis R, Desiderio MA. Hepatocyte growth factor-activated NF-kappaB regulates HIF-1 activity and ODC expression, implicated in survival, differently in different carcinoma cell lines. Carcinogenesis. 2004; 25: 20892100.
38. Frede S, Stockmann C, Freitag P, Fandrey J. Bacterial lipopolysaccharide induces HIF-1 activation in human monocytes via p44/42 MAPK and NF-kappaB. Biochem J. 2006; 396: 517527.[CrossRef][Medline] [Order article via Infotrieve]
39. Jung Y, Isaacs JS, Lee S, Trepel J, Liu ZG, Neckers L. Hypoxia-inducible factor induction by tumour necrosis factor in normoxic cells requires receptor-interacting protein-dependent nuclear factor kappa B activation. Biochem J. 2003; 370: 10111017.[CrossRef][Medline] [Order article via Infotrieve]
40. Jung YJ, Isaacs JS, Lee S, Trepel J, Neckers L. Microtubule disruption utilizes an NFkappa B-dependent pathway to stabilize HIF-1alpha protein. J Biol Chem. 2003; 278: 74457452.
41. Zhou J, Schmid T, Brune B. Tumor necrosis factor-alpha causes accumulation of a ubiquitinated form of hypoxia inducible factor-1alpha through a nuclear factor-kappaB-dependent pathway. Mol Biol Cell. 2003; 14: 22162225.
42. Dimova EY, Samoylenko A, Kietzmann T. Oxidative stress and hypoxia: implications for plasminogen activator inhibitor-1 expression. Antioxid Redox Signal. 2004; 6: 777791.[CrossRef][Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
M. R. Bonsignore and J. Eckel Metabolic aspects of obstructive sleep apnoea syndrome Eur. Respir. Rev., June 1, 2009; 18(112): 113 - 124. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Frede, C. Stockmann, S. Winning, P. Freitag, and J. Fandrey Hypoxia-Inducible Factor (HIF) 1{alpha} Accumulation and HIF Target Gene Expression Are Impaired after Induction of Endotoxin Tolerance J. Immunol., May 15, 2009; 182(10): 6470 - 6476. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. L. Deshmane, R. Mukerjee, S. Fan, L. Del Valle, C. Michiels, T. Sweet, I. Rom, K. Khalili, J. Rappaport, S. Amini, et al. Activation of the Oxidative Stress Pathway by HIV-1 Vpr Leads to Induction of Hypoxia-inducible Factor 1{alpha} Expression J. Biol. Chem., April 24, 2009; 284(17): 11364 - 11373. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. T. Taylor Interdependent roles for hypoxia inducible factor and nuclear factor-{kappa}B in hypoxic inflammation J. Physiol., September 1, 2008; 586(17): 4055 - 4059. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Klein, D. Flugel, and T. Kietzmann Transcriptional Regulation of Serine/Threonine Kinase-15 (STK15) Expression by Hypoxia and HIF-1 Mol. Biol. Cell, September 1, 2008; 19(9): 3667 - 3675. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Tacchini, E. Gammella, C. De Ponti, S. Recalcati, and G. Cairo Role of HIF-1 and NF-{kappa}B Transcription Factors in the Modulation of Transferrin Receptor by Inflammatory and Anti-inflammatory Signals J. Biol. Chem., July 25, 2008; 283(30): 20674 - 20686. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kondo, Y. Tang, E. A. Scheef, N. Sheibani, and C. M. Sorenson Attenuation of retinal endothelial cell migration and capillary morphogenesis in the absence of bcl-2 Am J Physiol Cell Physiol, June 1, 2008; 294(6): C1521 - C1530. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. L. Page, D. A. Chan, A. J. Giaccia, M. Levine, and D. E. Richard Hypoxia-inducible Factor-1{alpha} Stabilization in Nonhypoxic Conditions: Role of Oxidation and Intracellular Ascorbate Depletion Mol. Biol. Cell, January 1, 2008; 19(1): 86 - 94. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. BelAiba, S. Bonello, C. Zahringer, S. Schmidt, J. Hess, T. Kietzmann, and A. Gorlach Hypoxia Up-Regulates Hypoxia-Inducible Factor-1{alpha} Transcription by Involving Phosphatidylinositol 3-Kinase and Nuclear Factor {kappa}B in Pulmonary Artery Smooth Muscle Cells Mol. Biol. Cell, December 1, 2007; 18(12): 4691 - 4697. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Mizukami, Y. Kohgo, and D. C. Chung Hypoxia Inducible Factor-1 Independent Pathways in Tumor Angiogenesis Clin. Cancer Res., October 1, 2007; 13(19): 5670 - 5674. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2007 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |